---
title: "Investors in GSK plc Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - GSK"
description: "A class action lawsuit has been filed against GSK plc for alleged securities fraud affecting shareholders between February 5, 2020, and August 14, 2022. Investors who suffered losses are encouraged to"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/232279966.md"
published_at: "2025-03-18T16:31:45.000Z"
---

# Investors in GSK plc Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - GSK

> A class action lawsuit has been filed against GSK plc for alleged securities fraud affecting shareholders between February 5, 2020, and August 14, 2022. Investors who suffered losses are encouraged to contact Levi & Korsinsky LLP before April 7, 2025, to discuss their rights and potential recovery under federal securities laws. The lawsuit claims GSK misled investors regarding the withdrawal of Zantac from the market and the associated risks. Levi & Korsinsky has a strong track record in securities litigation and offers no-cost consultations for affected investors.

**NEW YORK, NY / ACCESS Newswire / March 18, 2025 /** If you suffered a loss on your **GSK plc** investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:

https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=136884&wire=1

or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.

<img height="0" src="https://app.accessnewswire.com/api/iframe.ashx?releaseid=1001778&url=https%3a%2f%2fwww.youtube.com%2fembed%2fTylLcsSEs2M" width="0"/></div></div></div><p><strong>THE LAWSUIT:</strong> A class action securities lawsuit was filed against GSK plc that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between February 5, 2020 and August 14, 2022.</p><p><strong>CASE DETAILS:</strong> According to the filed complaint, defendants represented to investors that GSK removed Zantac from the market "\[b\] ased on information available at the time and correspondence with regulators." GSK also stated that it was "continuing with investigations into the potential source of NDMA." Defendants also assured investors that "GSK, the FDA, and the EMA \[European Medicines Agency\] have all independently concluded that there is no evidence of a causal association between ranitidine therapy and the development of cancer in patients," findings that were "consistent with other ranitidine data published prior to 2019." Finally, defendants claimed that they could not "quantify or reliably estimate the liability." These representations were materially false or misleading. In truth, GSK was fully aware of the source of NDMA and had been for nearly 40 years before withdrawing Zantac from the market.</p><p><strong>WHAT'S NEXT?</strong> If you suffered a loss in GSK stock during the relevant time frame - even if you still hold your shares - go to <a href="https://pr.report/8f98" rel="nofollow">https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=136884&wire=1</a> to learn about your rights to seek a recovery. <strong>There is no cost or obligation to participate.</strong></p><p><strong>WHY LEVI & KORSINSKY:</strong> Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.</p><p><strong>CONTACT:</strong><br/>Levi & Korsinsky, LLP<br/>Joseph E. Levi, Esq.<br/>Ed Korsinsky, Esq.<br/>33 Whitehall Street, 17th Floor<br/>New York, NY 10004<br/><a href="mailto:jlevi@levikorsinsky.com" rel="nofollow">jlevi@levikorsinsky.com</a><br/>Tel: (212) 363-7500<br/>Fax: (212) 363-7171<br/><a href="https://pr.report/8f99" rel="nofollow">https://zlk.com/</a></p><p><strong>SOURCE:</strong> Levi & Korsinsky, LLP</p><br/><br/>View the original <a href="https://www.accessnewswire.com/newsroom/en/business-and-professional-services/investors-in-gsk-plc-should-contact-levi-and-korsinsky-before-ap-1001778">press release</a> on ACCESS Newswire<br/><br/><img height="0" src="https://app.accessnewswire.com/img.ashx?id=1001778" width="0"/></body></html>

### Related Stocks

- [GSK.UK - GlaxoSmithKline plc](https://longbridge.com/en/quote/GSK.UK.md)
- [GSK.US - GSK](https://longbridge.com/en/quote/GSK.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 葛兰素史克获得欧洲委员会对 Exdensur 的批准 | 葛兰素史克：葛兰素史克 - 欧洲委员会批准的 EXDENSUR | [Link](https://longbridge.com/en/news/276102835.md) |
| 葛兰素史克启动最多达 4.5 亿英镑的股票回购批次 | 葛兰素史克启动高达 4.5 亿英镑的股票回购计划 | [Link](https://longbridge.com/en/news/276103252.md) |
| 贝伦贝格银行维持对葛兰素史克（GSK）的持有评级 | Berenberg Bank 分析师 Kerry Holford 对葛兰素史克 (GSK) 维持了持有评级，目标价为 20.00 英镑。Holford 专注于医疗保健行业，推荐股票的平均回报率为 9.7%，成功率为 59.14%。此外，美国 | [Link](https://longbridge.com/en/news/276103203.md) |
| 葛兰素史克公司 - 董事/高管持股情况 | 葛兰素史克（GSK plc）于 2026 年 2 月 12 日宣布向其管理责任人（PDMRs）授予延期年度奖金计划奖励。根据葛兰素史克 2017 年延期年度奖金计划，执行董事需将部分奖金延期至普通股或美国存托股票（ADS），为期三年。值得注 | [Link](https://longbridge.com/en/news/276066255.md) |
| 葛兰素史克启动了第四批股票回购，金额最高可达 4.5 亿英镑，这是其 20 亿英镑回购计划的一部分 | 英国制药巨头葛兰素史克（GSK plc）宣布启动其 20 亿英镑股票回购计划的第四个阶段，计划回购高达 4.5 亿英镑的股份。这是在完成前三个阶段之后的举措。此次回购是 GSK 将多余资本返还给股东并提升每股收益的战略的一部分。股票购买将于 | [Link](https://longbridge.com/en/news/276103384.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
